Guangzhou Innogen Pharmaceutical Group Co., Ltd. engages in the production and distribution of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong and currently employs 105 full-time employees. The company went IPO on 2025-08-15. The firm is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The firm is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The firm principally conducts its businesses in the domestic market.
02591.HK stock price ended at $27.34 on jeudi, after dropping 1.01%
On the latest trading day Feb 12, 2026, the stock price of 02591.HK fell by 1.01%, dropping from $27.62 to $27.34. During the session, the stock saw a volatility of 3.01%, with prices oscillating between a daily low of $27.26 and a high of $28.08. On the latest trading day, the trading volume for 02591.HK decreased by 23.4K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 223.6K shares were traded, with a market value of approximately $11.4B.
Signaux Techniques de 02591.HK
Résumé des Signaux Techniques
Acheter des signaux 1
Signaux neutres 1
Signaux de vente 5
Strong Sell
Sell
Neutral
Buy
Strong Buy
02591.HK présente actuellement 1 signaux d'achat et 5 signaux de vente. L'action est en Tendance baissière depuis 12:00 AM, avec une variation totale du prix de -1.3% pendant cette période. En général, les indicateurs techniques indiquent une tendance Strong Sell à moyen terme.
Signaux haussiers/baissiers pour 02591.HK
Nous analysons les indicateurs clés comme les moyennes mobiles, le RSI, le MACD et le volume de transactions pour générer des signaux haussiers et baissiers pour 02591.HK, vous aidant à prendre des décisions d'investissement éclairées.